We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| T2 Biosystems Inc | NASDAQ:TTOO | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 2.05 | 49.28% | 6.21 | 6.20 | 6.25 | 6.5556 | 4.61 | 4.61 | 3,152,259 | 01:00:00 |
From May 2019 to May 2024
The first conference is the Janney Healthcare Conference 2018, which is being held September 17-18 in New York City. This conference will allow institutional investors to meet with the Company but does not include a formal webcast presentation. The Company will be available to meet with investors on September 17.
The second conference is the Cantor Global Healthcare Conference, which is being held October 1-3 in New York City. The Company is scheduled to present at the Cantor conference on Tuesday, October 2, 2018 at 8:35 a.m. ET and will be available for one-on-one meetings during the conference. The presentation will be webcast live and available for replay and may be accessed by visiting the Investors/Events & Presentations section of the Company’s website at www.t2biosystems.com. A replay of the webcast will be available shortly after the conclusion of the presentation and will be archived on the Company's website for 90 days following the presentation.
About T2 Biosystems:T2 Biosystems, an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, T2Candida® Panel, and T2Bacteria® Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including products for the detection of additional species and antibiotic resistance markers of sepsis pathogens, and tests for Lyme disease. For more information, please visit www.t2biosystems.com.
Media Contact: Gina Kent, Vault Communicationsgkent@vaultcommunications.com610-455-2763
Investor Contact: Matthew Clawson, W2O Groupmclawson@w2ogroup.com949-370-8500
1 Year T2 Biosystems Chart |
1 Month T2 Biosystems Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
